ArticleFrontiers in oncology2022

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer.

Shen Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.